For US residents only.

KISQALI Is Now FDA Approved

An option for postmenopausal women with HR+ (ER+ and/or PR+), HER2- metastatic breast cancer, in combination with hormone therapy

Important Safety Information:

What is the most important information I should know about KISQALI?

KISQALI may cause serious side effects, including:

Heart rhythm problems (QT prolongation). KISQALI can cause a heart problem kno

... See More
Approved Use:

KISQALI® (ribociclib) is a prescription medicine used in combination with a certain type of medicine as the first hormonal-based therapy to treat women who have gone through menopause with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negati

... See More
KISQALI MEDICATION INFORMATION

Treatment Information

Explore details about treatment with KISQALI, including side effect information and dosing instructions.

LEARN MORE
SUPPORT MADE SIMPLE

Patient Support

The KISQALI Care Patient Support Program offers customized services and information about financial assistance options.

LEARN MORE

INDICATION

KISQALI® (ribociclib) is a prescription medicine used in combination with a certain type of medicine as the first hormonal-based therapy to treat women who have gone through menopause with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer that has spread to other parts of the body (metastatic).

It is not known if KISQALI is safe and effective in children.

IMPORTANT SAFETY INFORMATION

What is the most important information I should know about KISQALI?

KISQALI may cause serious side effects, including:

Heart rhythm problems (QT prolongation). KISQALI can cause a heart problem known as QT prolongation. This condition can cause an abnormal heartbeat and may lead to death. Your health care provider should check your heart and do blood tests before and during treatment with KISQALI. Tell your health care provider right away if you have a change in your heartbeat (a fast or irregular heartbeat), or if you feel dizzy or faint.

Liver problems (hepatobiliary toxicity). KISQALI can cause serious liver problems. Your health care provider should do blood tests to check your liver before and during treatment with KISQALI. Tell your health care provider right away if you get any of the following signs and symptoms of liver problems:

  • yellowing of your skin or the whites of your eyes (jaundice)
  • dark or brown (tea-colored) urine
  • feeling very tired
  • loss of appetite
  • pain on the right side of your stomach area (abdomen)
  • bleeding or bruising more easily than normal

Low white blood cell counts (neutropenia). Low white blood cell counts are very common when taking KISQALI and may result in infections that may be severe. Your health care provider should check your white blood cell counts before and during treatment with KISQALI. Tell your health care provider right away if you have signs and symptoms of low white blood cell counts or infections such as fever and chills.

Your health care provider may tell you to decrease your dose, temporarily stop, or completely stop taking KISQALI if you develop certain serious side effects during treatment with KISQALI.

What should I tell my health care provider before taking KISQALI?

Before you take KISQALI, tell your health care provider if you:

  • have any heart problems, including heart failure, irregular heartbeats, and QT prolongation
  • have ever had a heart attack
  • have a slow heartbeat (bradycardia)
  • have problems with the amount of potassium, calcium, phosphorus, or magnesium in your blood
  • have fever, chills, or any other signs or symptoms of infection
  • have liver problems
  • have any other medical conditions
  • are pregnant, or plan to become pregnant. KISQALI can harm your unborn baby
    • If you are able to become pregnant, your health care provider should do a pregnancy test before you start treatment with KISQALI.
    • Females who are able to become pregnant and who take KISQALI should use effective birth control during treatment and for at least 3 weeks after the last dose of KISQALI.
    • Talk to your health care provider about birth control methods that may be right for you during this time.
    • If you become pregnant or think you are pregnant, tell your health care provider right away.
  • are breastfeeding or plan to breastfeed. It is not known if KISQALI passes into your breast milk. Do not breastfeed during treatment with KISQALI and for at least 3 weeks after the last dose of KISQALI

Tell your health care provider about all of the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. KISQALI and other medicines may affect each other causing side effects. Know the medicines you take. Keep a list of them to show your health care provider or pharmacist when you get a new medicine.

What should I avoid while taking KISQALI?

Avoid eating pomegranate or grapefruit and avoid drinking pomegranate or grapefruit juice during treatment with KISQALI since these may increase the amount of KISQALI in your blood.

The most common side effects of KISQALI include:

  • nausea
  • tiredness
  • diarrhea
  • hair loss
  • vomiting
  • constipation
  • headache
  • back pain

KISQALI may cause fertility problems if you are male and take KISQALI. This may affect your ability to father a child. Talk to your health care provider if this is a concern for you.

Tell your health care provider if you have any side effect that bothers you or that does not go away.

These are not all of the possible side effects of KISQALI. For more information, ask your health care provider or pharmacist. Call your doctor for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088.

Please see full Prescribing Information including Patient Information.